Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.09 EPS

Puma Biotechnology (NASDAQ:PBYI) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09, FiscalAI reports. Puma Biotechnology had a return on equity of 20.81% and a net margin of 10.69%.The business had revenue of $44.81 million during the quarter, compared to analyst estimates of $42.00 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• ALISCA‑Lung1 interim: higher‑dose alisertib (60 mg) showed a median PFS of 4.2 months versus 1.7 months at 50 mg and activity is enriched in c‑MYC‑high tumors; dose escalation to 70 mg and a combination ALISCA‑Lung2 (with paclitaxel) are planned for H2 2026.
• ALISCA‑Breast1 interim: alisertib plus endocrine therapy showed median PFS ~5.45–5.59 months in the 40–50 mg arms with stronger efficacy in biomarker subgroups (PIK3CA wild‑type, ESR1‑mutant and high c‑MYC); enrollment will be expanded to biomarker‑focused cohorts and updated data are expected H2 2026.
• Financials & guidance: raised FY2026 net NERLYNX product revenue guidance to $202–206M, expects FY net income of $16–19M, and is now debt‑free after the final Athyrium payment with ~$101.5M in cash/marketable securities as of 3/31/2026.
• Q1 commercial softness: Q1 net product revenue fell to $42.0M (2,328 ex‑factory bottles, down ~29% QoQ) driven in part by an estimated ~439‑bottle inventory drawdown at specialty channels; TRXs were down ~4% QoQ and demand declined ~6% QoQ despite higher NRX and enrollment trends.

Puma Biotechnology Price Performance

PBYI traded up $0.23 during trading hours on Friday, reaching $7.49. 755,011 shares of the stock traded hands, compared to its average volume of 267,164. The firm’s fifty day simple moving average is $6.81 and its two-hundred day simple moving average is $6.19. The company has a market cap of $381.17 million, a price-to-earnings ratio of 15.60 and a beta of 1.24. Puma Biotechnology has a fifty-two week low of $2.85 and a fifty-two week high of $7.90.

Wall Street Analysts Forecast Growth

PBYI has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Puma Biotechnology in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Institutional Investors Weigh In On Puma Biotechnology

A number of large investors have recently added to or reduced their stakes in PBYI. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at approximately $36,000. BNP Paribas Financial Markets raised its position in shares of Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares in the last quarter. Abel Hall LLC acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $64,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Puma Biotechnology in the 1st quarter valued at approximately $66,000. Finally, Ieq Capital LLC acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $68,000. 61.29% of the stock is owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.